GlassScriptPhysician profile
Jenny Browning
NPI 1982232708
$7,546.45
in general payments reported to CMS, 2019-2025
31 companies · $20.36 in 2025
The $20.36 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $1,913 · 2023: $2,766 · 2024: $1,719 · 2025: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,213.85 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $902.59 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $759.21 | 2022-2024 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $479.54 | 2021-2024 | Entyvio |
| Pfizer INC. | $402.69 | 2021-2024 | |
| Ardelyx, INC. | $364.30 | 2022-2024 | Ibsrela |
| Genzyme Corporation | $347.01 | 2023-2024 | |
| Celgene Corporation | $329.91 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $216.84 | 2021-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $174.75 | 2023 | Stelara |
| Gilead Sciences, INC. | $172.25 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $160.01 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $130.62 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $127.40 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Evoke Pharma, INC. | $122.24 | 2022-2023 | Gimoti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.88 | 2021-2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $98.59 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $90.55 | 2024 | |
| Qol Medical, LLC | $61.28 | 2023 | Sucraid |
| Genentech USA, INC. | $51.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $42.59 | 2024 | Voquezna |
| Sandoz INC. | $28.73 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.81 | 2023 | Cyltezo |
| Biocon Biologics INC | $20.36 | 2025 | Yesintek |
| Mylan Institutional INC. | $20.00 | 2023 | Hulio |
| Dexcom, INC. | $15.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.62 | 2022 | |
| Organon LLC | $14.51 | 2024 | |
| Daiichi Sankyo INC. | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.